Test-negative case-control design shows BNT162b2 effectiveness against COVID-19 in children, suggesting continued vaccination is beneficial.
In a test-negative case-control design among children aged 6 months–4 years (n=11,878) and 5–17 years (n=16,687) in Kaiser Permanente Southern California, BNT162b2 2024–2025 effectiveness against hospitalization/emergency department/urgent care/outpatient was 36% (95% CI: -5-61%) and 42% (-2-67%), respectively suggesting pediatric COVID-19 vaccination remains beneficial.
No takes yet. Share an insight, caveat, or question.
Tartof et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: